CHMP adopts negative opinion over osteoporosis drug Evenity

This article was originally published here

The agency said that as the benefits of Evenity did not outweigh its risks, it recommended refusal of the drug’s marketing authorisation. The marketing authorisation application (MAA) of

The post CHMP adopts negative opinion over osteoporosis drug Evenity appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply